Sigilon Therapeutics
Cambridge
About Sigilon Therapeutics
Sigilon Therapeutics is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. To address these therapy problems, Sigilon is developing its Shielded Living TherapeuticsTM platform. Sigilon is designing product candidates to provide a wide range of functions or therapeutic molecules that may be missing or deficient in the body, leveraging advances in cell differentiation and engineering, as well as cutting-edge innovations in its proprietary biocompatible materials’potentially resulting in functional cures for patients with a wide range of acute and chronic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $263.2M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2020)
- Ticker: nasdaq:SGTX
- Website: sigilon.com
- Phone: 617-336-7540
Industries & Categories
Biotechnology, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/sigilon-therapeutics-190774 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.